Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
US9675594B2 · kind B2 · utility
3Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 2016 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Oct 7, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to arylpyrrolopyridine derivatives of Formula A:The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.